OB polypeptides and modified forms as modulators of body weight

• US 6,350,730 B1
• Filed: 06/07/1995
• Issued: 02/26/2002
• Est. Priority Date: 08/17/1994
• Status: Expired due to Term

• Current Assignee: Rockefeller University
• Original Assignee: Rockefeller University
• Inventors: Proenca, Ricardo, Friedman, Jeffrey M., Zhang, Yiying
• Primary Examiner(s): Saoud, Christine J.
• Application Number:
  US08/488,223
• Time in Patent Office: 2,456 Days
• Field of Search: 424/851, 512/2, 512/8, 512/12, 512/844, 512/866, 512/909, 512/350, 530/421
• US Class Current: 514/4.8
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 8/64 Proteins; Peptides; Derivatives or degradation products thereof
• CPC Class Codes: A61Q 19/06 for countering cellulitis
• CPC Class Codes: C07K 14/5759 Products of obesity genes, e.g. leptin, obese (OB), tub, fat
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/26 against hormones ; against hormone releasing or inhibiting factors
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

The present invention relates generally to the control of body weight of animals including mammals and humans, and more particularly to materials identified herein as modulators of body weight, and to diagnostic and therapeutic uses of such modulators. In one of its broadest aspects, the present invention relates to nucleotide sequences corresponding to the murine and human OB gene, and two isoforms thereof, and proteins expressed by such nucleotides or degenerate variations thereof, that demonstrate the ability to participate in the control of mammalian body weight and that have been postulated to play a critical role in the regulation of body weight and adiposity. The present invention further provides nucleic acid molecules for use as molecular probes or as primers for polymerase chain reaction (PCR) amplification. In further aspects, the present invention provides cloning vectors and mammalian expression vectors comprising the nucleic acid molecules of the invention. The invention further relates to host cells transfected or transformed with an appropriate expression vector and to their use in the preparation of the modulators of the invention. Also provided are antibodies to the OB polypeptide. Moreover, a method for modulating body weight of a mammal is provided.

Claims

1. A method for modifying body weight of an animal, the method comprising administering to the animal an effective amount of an OB polypeptide analog, capable of modulating body weight, comprising amino acids 22-167 of SEQ ID NOS:

2 or 4, wherein one or more amino acids selected from the group consisting of amino acids 53, 56, 71, 85, 89, 92, 95, 98, 110, 118, 121, 122, 126, 127, 128, 129, 132, 139, 157, 159, 163, and 166 is substituted with another amino acid.

8. The method according to claim 1, 2, 3, 4, 5, 6, or 7 wherein the OB polypeptide or polypeptide analog is a recombinant polypeptide or polypeptide analog.

9. The method according to claim 1, 2, 3, 4, 5, 6, or 7 wherein the OB polypeptide or polypeptide analog is a chemically synthesized polypeptide or polypeptide analog.

10. The method according to claim 1, 2, 3, 4, 5, 6, or 7 wherein the OB polypeptide or polypeptide analog has one or more polymers attached thereto.

11. The method according to claim 10, wherein at least one of said polymers is a water-soluble polymer.

12. The method according to claim 11, wherein the water-soluble polymer is polyethylene glycol.

13. The method according to claim 12, wherein the polypeptide or polypeptide analog is mono-, di-, tri- or tetrapegylated.

14. The method according to claim 13 wherein the polypeptide or polypeptide analog is N-terminal monopegylated.

15. The method according to claim 10, wherein at least one of said polymers is a pharmaceutically acceptable polymer.

16. The method according to claim 15, wherein said pharmaceutically acceptable polymer is a water soluble polymer.

17. The method according to claim 10, wherein at least one of said polymers is a polyamino acid.

18. The method according to claim 10, wherein at least one of said polymers is a branched or unbranched polymer.

19. The method according to claim 10, wherein at least one of said polymers is N-terminally attached to said polypeptide or polypeptide analog.

20. The method according to claim 10, wherein at least one of said polymers is C-terminally attached to said polypeptide or polypeptide analog.

21. The method according to claim 10, wherein at least one of said polymers is attached by at least one covalent bond through an amino acid residue of said polypeptide or polypeptide analog via a reactive group.

22. The method according to claim 21, wherein said reactive group is a free amino or carboxyl group.

23. The method according to claim 21, wherein said amino acid residue is selected from the group consisting of lysine, aspartic acid and glutamic acid.

24. The method according to claim 10, wherein the number of said polymers attached is one, two, three or four.

25. The method according to claim 24 wherein said two, three or four polymers are the same polymer.

26. The method according to claim 24 wherein said two, three or four polymers are two, three or four different polymers.

27. The method according to claim 1, 2, 3, 4, 5, 6 or 7 wherein the OB polypeptide or polypeptide analog is administered by intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, nasal, oral or pulmonary delivery.

2. A method for modifying body weight of an animal, the method comprising administering to the animal an effective amount of an OB polypeptide analog, capable of modulating body weight, comprising amino acids 22-167 of SEQ ID NO:

4 wherein the analog is selected from the group consisting of polypeptides wherein;

(a) the serine residue at position 53 is substituted with glycine, alanine, valine, cysteine, methionine, or threonine;

(b) the serine residue at position 98 is substituted with glycine, alanine, valine, cysteine, methionine, or threonine; and

(c) the arginine residue at position number 92 is substituted with asparagine, lysine, histidine, glutamine, glutamic acid, aspartic acid, serine, threonine, methionine, or cysteine.

3. A method for modifying body weight of an animal, the method comprising administering to the animal an effective amount of an OB polypeptide, capable of modulating body weight, comprising amino acids 22-167 of SEQ ID NOS:

2 or 4 or amino acids 22-166 of SEQ ID NO;

5 or 6 wherein said polypeptide has an N-terminal amino acid sequence selected from the group consisting of;

(a) SEQ ID NO;

38;

(b) SEQ ID NO;

98;

(c) SEQ ID NO;

26;

(d) SEQ ID NO;

27;

(e) SEQ ID NO;

28;

(f) SEQ ID NO;

99; and

(g) glycine-serine-proline.

4. A method for modifying body weight of an animal, the method comprising administering to the animal an effective amount of an OB polypeptide analog, capable of modulating body weight, comprising amino acids 22-167 of SEQ ID NOS:

2 or 4, wherein one or more amino acids selected from the group consisting of amino acids 53, 56, 71, 85, 89, 92, 95, 98, 110, 118, 121, 122, 126, 127, 128, 129, 132, 139, 157, 159, 163, and 166 is substituted with another amino acid and wherein said analog has an N-terminal amino acid sequence selected from the group consisting of;

(a) SEQ ID NO;

38;

(b) SEQ ID NO;

98;

(c) SEQ ID NO;

26;

(d) SEQ ID NO;

27;

(e) SEQ ID NO;

28;

(f) SEQ ID NO;

99; and

(g) glycine-serine-proline.

5. A method for modifying body weight of an animal, the method comprising administering to the animal an effective amount of an OB polypeptide analog, capable of modulating body weight, comprising amino acids 22-166 of SEQ ID NOS:

5 or 6, wherein one or more amino acids selected from the group consisting of amino acids 52, 55, 70, 84, 88, 91, 94, 97, 109, 117, 120, 121, 125, 126, 127, 128, 131, 138, 156, 158, 162, and 165 is substituted with another amino acid.

6. A method for modifying body weight of an animal, the method comprising administering to the animal an effective amount of an OB polypeptide analog, capable of modulating body weight, comprising amino acids 22-166 of SEQ ID NO:

6 wherein the analog is selected from the group consisting of polypeptides wherein;

(a) the serine residue at position 52 is substituted with glycine, alanine, valine, cysteine, methionine, or threonine;

(b) the serine residue at position 97 is substituted with glycine, alanine, valine, cysteine, methionine, or threonine; and

(c) the arginine residue at position number 91 is substituted with asparagine, lysine, histidine, glutamine, glutamic acid, aspartic acid, serine, threonine, methionine, or cysteine.

7. A method for modifying body weight of an animal, the method comprising administering to the animal an effective amount of an OB polypeptide analog, capable of modulating body weight, comprising amino acids 22-166 of SEQ ID NOS:

5 or 6, wherein one or more amino acids selected from the group consisting of amino acids 52, 55, 70, 84, 88, 91, 94, 97, 109, 117, 120, 121, 125, 126, 127, 128, 131, 138, 156, 158, 162, and 165 is substituted with another amino acid and wherein said analog has an N-terminal amino acid sequence selected from the group consisting of;

(a) SEQ ID NO;

38;

(b) SEQ ID NO;

98;

(c) SEQ ID NO;

26;

(d) SEQ ID NO;

27;

(e) SEQ ID NO;

28;

(f) SEQ ID NO;

99; and

(g) glycine-serine-proline.